同期整合加量调强放疗在食管癌中的应用进展

doi:10.3760/cma.j.cn113030-20210120-00035

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract In recent years, unconventional fractionated radiotherapy has shown increasing advantages in the treatment of multiple system tumors. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) involves the delivery of standard-fraction doses of radiotherapy to different areas, achieving the delivery of higher doses of radiotherapy per fraction to the high-risk gross tumor volume (GTV) without sacrificing the irradiation dose to the normal tissues. The dosimetric advantages of SIB-IMRT have been widely recognized. At present, the local control,survival advantage, indication population and the optimal upper limit of single fraction of SIB-IMRT for esophageal carcinoma are still unclear. This article reviews the application of SIB-IMRT in esophageal carcinoma.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Lan
	Wang Yamin
	Liu Lihong
	Liu Shutang
	Han Chun
	Yu Jinming

Key words： Esophageal neoplasm/intensity-modulated radiotherapy Simultaneous integrated boost Application progress

Received: 20 January 2021

Fund:National Key Research&Development Program Project (2018YFC1313203);Institute of Hospital Management Project of National Health and Family Planning Commission (WJWYGS-201816)

Corresponding Authors: Han Chun, Email:hanchun2006@126.com

Cite this article:

Wang Lan,Wang Yamin,Liu Lihong et al. Research progress on application of simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma[J]. Chinese Journal of Radiation Oncology, 2021, 30(11): 1216-1220.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20210120-00035 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2021/V30/I11/1216

[1] Franceschini D, Paiar F, Meattini I, et al. Simultaneous integrated boost-intensity modulated radiotherapy in head and neck cancer[J]. Laryngoscope, 2013, 123(12):E97-E103. DOI:10.1002/lary.24257.
[2] Leclerc M, Maingon P, Hamoir M, et al. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach[J]. Radiother Oncol, 2013, 106(3):333-340. DOI:10.1016/j.radonc.2013.03.002.
[3] Jin X, Yi J, Zhou Y, et al. A new plan quality index for nasopharyngeal cancer SIB IMRT[J]. Phys Med, 2014, 30(1):122-127. DOI:10.1016/j.ejmp.2013.03.007.
[4] Yi J, Huang X, Gao L, et al. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma[J]. Radiat Oncol, 2014, 9:56. DOI:10.1186/1748-717X-9-56.
[5] Hakariya T, Obata S, Igawa T, et al. Feasibility of simultaneous integrated boost IMRT (SIB-IMRT) for castration-resistant prostate cancer[J]. Anticancer Res, 2014, 34(8):4261-4265. DOI:10.1016/j.urolonc.2014.05.010.
[6] Franco P, Arcadipane F, Ragona R, et al. Locally advanced (T3-T4 or N) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy[J]. Anticancer Res, 2016, 36(4):2027-2032.
[7] Tomasoa NB, Meulendijks D, Nijkamp J, et al. Clinical outcome in patients treated with simultaneous integrated boost-intensity modulated radiation therapy (SIB-IMRT) with and without concurrent chemotherapy for squamous cell carcinoma of the anal canal[J]. Acta Oncol, 2016, 55(6):760-766. DOI:10.3109/0284186X.2015.1124141.
[8] Fu WH, Wang LH, Zhou ZM, et al. Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma[J]. World J Gastroenterol, 2004, 10(8):1098-1102. DOI:10.3748/wjg.v10.i8.1098.
[9] Welsh J, Palmer MB, Ajani JA, et al. Esophageal cancer dose escalation using a simultaneous integrated boost technique[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):468-474. DOI:10.1016/j.ijrobp.2010.10.023.
[10] Zhang WZ, Chen JZ, Li DR, et al. Simultaneous modulated accelerated radiation therapy for esophageal cancer:a feasibility study[J]. World J Gastroenterol, 2014, 20(38):13973-13980. DOI:10.3748/wjg.v20.i38.13973.
[11] Huang BT, Huang RH, Zhang WZ, et al. Different definitions of esophagus influence esophageal toxicity prediction for esophageal cancer patients aDministered simultaneous integrated boost versus standard-dose radiation therapy[J]. Sci Rep, 2017, 7(1):120. DOI:10.1038/s41598-017-00168-x.
[12] Yu WW, Zhu ZF, Fu XL, et al. Simultaneous integrated boost intensity modulated radiotherapy in esophageal carcinoma:early results of a phase Ⅱ study[J]. Strahlenther Onkol, 2014, 190(11):979-986. DOI:10.1007/s00066-014-0636-y.
[13] 白文文,宋玉芝,刘明,等. SIB-IMRT技术在颈及胸上段食管癌中的临床应用[J]. 中华肿瘤防治杂志,2016, 23(4):248-252. DOI:10.16073/j.cnki.cjcpt.2016.04.010.
Bai WW, Song YZ, Liu M, et al. Clinical application of simultaneous integrated boost intensity-modulated radiation therapy in cervical and upper esophageal carcinoma[J]. Chin J Cancer Prevent Treat, 2016, 23(4):248-252. DOI:10.16073/j.cnki.cjcpt.2016.04.010.
[14] 白文文,付丽媛,李静,等. 食管癌同期推量调强放疗和后程缩野加量调强放疗的临床对比研究[J]. 中华放射医学与防护杂志,2018, 38(4):258-264. DOI:10.3760/cma.j.issn.0254-5098.2018.04.004.
Bai WW, Fu LY, Li J, et al. Comparison of simultaneous integrated boost and late course boost intensity-modulated radiation therapy in the treatment of esophageal carcinoma[J]. Chin J Radiol Med Protect, 2018, 38(4):258-264. DOI:10.3760/cma.j.issn.0254-5098.2018.04.004.
[15] 王澜,梁健,韩春,等. 同期整合加量调强放疗与常规分割放射治疗食管鳞癌的生存获益分析[J]. 中华放射肿瘤学杂志,2018, 27(11):965-970. DOI:10.3760/cma.j.issn.1004-4221.2018.11.003.
Wang L, Liang J, Han C, et al. Comparison of survival benefits between simultaneous integrated boost intensity-modulated radiotherapy and conventional fractionated radiotherapy for esophageal squamous cell carcinoma[J]. Chin J Radiat Oncol, 2018, 27(11):965-970. DOI:10.3760/cma.j.issn.1004-4221.2018.11.003.
[16] Xu YJ, Wang C, Liu G, et al. The efficacy and safety of simultaneous integrated boost intensity modulated radiation therapy for esophageal squamous cell carcinoma in Chinese population:a single institution experience[J]. J Cancer Res Ther, 2016, 12(1):82-88. DOI:10.4103/0973-1482.191640.
[17] 沈文斌,郭娜,祝淑钗,等. 选择性增加PTV单次剂量对食管癌患者预后的影响[J]. 肿瘤防治研究,2019, 46(5):463-469. DOI:10.3971/j.issn.1000-8578.2019.18.2007.
Shen WB, Guo N. Zhu SC, et al. Effect of selective increase of single dose of PTV on prognosis of patients with esophageal cancer[J]. Cancer Res Prevent Treat, 2019, 46(5):463-469. DOI:10.3971/j.issn.1000-8578.2019.18.2007.
[18] 白文文,宋玉芝,乔永志,等. 食管鳞癌SIB-IMRT疗效及预后因素分析[J]. 中华放射肿瘤学杂志,2018, 27(6):570-575. DOI:10.3760/cma.j.issn.1004-4221.2018.06.007.
Bai WW, Song YZ, Qiao YZ. Clinical efficacy and prognostic factors of simultaneous integrated boost intensity-modulated radiation therapy for esophageal squamous cell carcinoma[J]. Chin J Radiat Oncol, 2018, 27(6):570-575. DOI:10.3760/cma.j.issn.1004-4221.2018.06.007.
[19] Chen Li, Wenjie Ni, Xin Wang, et al. A phase Ⅰ/Ⅱ radiation dose escalation trial using simultaneous integrated boost technique with elective nodal irradiation and concurrent chemotherapy for unresectable esophageal cancer[J]. Radiat Oncol, 2019, 14(1):48-56. DOI:10.1186/s13014-019-1249-5.
[20] Sakanaka K, Ishida Y, FujII K, et al. Radiation dose-escalated chemoradiotherapy using simultaneous integrated boost intensity-modulated radiotherapy for locally advanced unresectable thoracic esophageal squamous cell carcinoma:a single-institution phase I study[J]. Clin Oncol (R Coll Radiol), 2020, S0936-6555(20):30294-302966. DOI:10.1016/j.clon.2020.07.012.
[21] Chen DW, Menon H, Verma V, et al. Results of a phase1/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer[J]. JAMA Oncol, 2019:2809. DOI:10.1186/s13014-019-1249-5.
[22] Yu W, Cai YW, Liu Q, et al. Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by (18) FDG-PET/CT for esophageal cancer[J]. Radiother Oncol, 2015, 114(2):195-200. DOI:10.1016/j.radonc.2014.12.007.